InVitae Corp (NASDAQ:NVTA) was upgraded by equities research analysts at Benchmark Co. from a “hold” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports.
A number of other research firms have also recently commented on NVTA. Zacks Investment Research raised shares of InVitae Corp from a “sell” rating to a “hold” rating in a report on Tuesday. Leerink Swann assumed coverage on shares of InVitae Corp in a report on Thursday, November 10th. They issued an “outperform” rating and a $12.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $10.81.
InVitae Corp (NASDAQ:NVTA) opened at 9.16 on Tuesday. The firm’s market capitalization is $297.20 million. The company has a 50-day moving average of $8.62 and a 200-day moving average of $8.07. InVitae Corp has a 1-year low of $5.76 and a 1-year high of $11.85.
InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings data on Monday, February 13th. The company reported ($0.69) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.04. The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $8.82 million. During the same period in the prior year, the company earned ($0.76) EPS. The company’s revenue for the quarter was up 187.5% compared to the same quarter last year. On average, equities analysts predict that InVitae Corp will post ($3.08) earnings per share for the current year.
“InVitae Corp (NVTA) Upgraded to “Buy” at Benchmark Co.” was first published by sleekmoney and is owned by of sleekmoney. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at http://sleekmoney.com/invitae-corp-nvta-upgraded-to-buy-at-benchmark-co/1659847.html.
In other InVitae Corp news, Director Geoffrey Crouse acquired 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 18th. The stock was acquired at an average price of $6.25 per share, for a total transaction of $93,750.00. Following the acquisition, the director now directly owns 34,259 shares in the company, valued at $214,118.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Randal W. Scott acquired 66,666 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was acquired at an average price of $6.00 per share, with a total value of $399,996.00. Following the acquisition, the chairman now owns 3,506,225 shares in the company, valued at $21,037,350. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 814,999 shares of company stock valued at $4,893,744.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Metropolitan Life Insurance Co. NY acquired a new position in shares of InVitae Corp during the second quarter worth about $142,000. BlackRock Inc. raised its position in shares of InVitae Corp by 1.2% in the third quarter. BlackRock Inc. now owns 33,064 shares of the company’s stock worth $290,000 after buying an additional 408 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of InVitae Corp by 95.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 44,528 shares of the company’s stock worth $330,000 after buying an additional 21,794 shares during the period. HighTower Advisors LLC raised its position in shares of InVitae Corp by 24.1% in the third quarter. HighTower Advisors LLC now owns 95,742 shares of the company’s stock worth $840,000 after buying an additional 18,578 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of InVitae Corp during the fourth quarter worth about $879,000.
InVitae Corp Company Profile
Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/invitae-corp-nvta-upgraded-to-buy-at-benchmark-co/1659847.html
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.